This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Stephen R. Marder, MD; Theodore Van Putten, MD; Jim Mintz, PhD; Joanne McKenzie, RN; Malca Lebell, PhD; Gary Faltico, PhD; Philip R.A. May, MD

Arch Gen Psychiatry. 1984;41(11):1025-1029.

Abstract
• The relative costs and benefits of low- and conventionaldose neuroleptic maintenance therapy were evaluated in a double-blind comparison of 5 and 25 mg of fluphenazine decanoate administered every two weeks. Subjects were 50 patients fulfilling DSM-III criteria for schizophrenic disorder who had been successfully maintained with 25 mg or less of fluphenazine decanoate. A one-year survival analysis disclosed that there were no statistically significant differences between the two doses insofar as preventing relapse. Patients receiving the higher dose appeared to feel more uncomfortable, as indicated by higher scores on subscales of the Hopkins Symptom Checklist-90. In addition, patients receiving the higher dose had higher side-effect scores. These findings suggest that a substantial proportion of patients who are presently maintained with 25 mg or less of fluphenazine decanoate every two weeks will do just as well with as little as 5 mg.

Author Affiliations
From the Veterans Administration Medical Center, Brentwood Division, Los Angeles (Drs Marder, Van Putten, Mintz, Lebell, Faltico, and May, and Ms McKenzie), and the Department of Psychiatry and Behavioral Sciences, UCLA (Drs Marder, Van Putten, Mintz, Faltico, and May).

Footnotes
Accepted for publication May 1, 1984.

Reprint requests to VA Medical Center, Brentwood Division, 11301 Wilshire Blvd, Los Angeles, CA 90073 (Dr Marder).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride
Linden et al.
J Psychopharmacol 2006;20:815-823.
ABSTRACT  

Maintenance Medication for Schizophrenia: Strategies for Dose Reduction
Schooler
Focus 2004;2:175-186.
ABSTRACT | FULL TEXT  

The Relationship of Clozapine and Haloperidol Treatment Response to Prefrontal, Hippocampal, and Caudate Brain Volumes
Arango et al.
Am. J. Psychiatry 2003;160:1421-1427.
ABSTRACT | FULL TEXT  

A Multidose Study of Haloperidol Decanoate in the Maintenance Treatment of Schizophrenia
Kane et al.
Am. J. Psychiatry 2002;159:554-560.
ABSTRACT | FULL TEXT  

Schizophrenia: early warning signs
Birchwood et al.
Adv. Psychiatr. Treat. 2000;6:93-101.
FULL TEXT  

Relapse and Rehospitalization During Maintenance Treatment of Schizophrenia: The Effects of Dose Reduction and Family Treatment
Schooler et al.
Arch Gen Psychiatry 1997;54:453-463.
ABSTRACT  

Schizophrenia
Kane
NEJM 1996;334:34-42.
FULL TEXT  

A Controlled Dose Comparison of Haloperidol in Newly Admitted Schizophrenic Patients
Van Putten et al.
Arch Gen Psychiatry 1990;47:754-758.
ABSTRACT  

Fluphenazine Dose, Clinical Response, and Extrapyramidal Symptoms During Acute Treatment
Levinson et al.
Arch Gen Psychiatry 1990;47:761-768.
ABSTRACT  

Dose of Fluphenazine, Familial Expressed Emotion, and Outcome in Schizophrenia: Results of a Two-Year Controlled Study
Hogarty et al.
Arch Gen Psychiatry 1988;45:797-805.
ABSTRACT  

Central D2-Dopamine Receptor Occupancy in Schizophrenic Patients Treated With Antipsychotic Drugs
Farde et al.
Arch Gen Psychiatry 1988;45:71-76.
ABSTRACT  

Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of Psychoses
Baldessarini et al.
Arch Gen Psychiatry 1988;45:79-91.
ABSTRACT  

Low- and Conventional-Dose Maintenance Therapy With Fluphenazine Decanoate: Two-Year Outcome
Marder et al.
Arch Gen Psychiatry 1987;44:518-521.
ABSTRACT  

Toward a More Reliable Diagnosis of Akathisia
Van Putten and Marder
Arch Gen Psychiatry 1986;43:1015-1016.
ABSTRACT  

Selection of Neuroleptic Dosage
Teicher and Baldessarini
Arch Gen Psychiatry 1985;42:636-637.
ABSTRACT